Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Cancer Chemotherapy and Pharmacology
Amita PatnaikDavid Hong

Abstract

The original version of this article unfortunately contained a mistake. The co-authors' names were incorrect.

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.